Products View Videos
Technology helps detect meth
High tech meth detector
Technology used to prevent dosage errors
Press Center >
Press Release
CDEX ANNOUNCES the Addition of heparin signatures to valimed™ to address medication errors and contamination
The ValiMed™ Signature Library of 167 signatures now has seven signatures of heparin such as produced by Baxter Healthcare Corporation (NYSE: BAX) and Hospira Inc (NYSE: HSP), including typical neonatal and pediatric doses
Tucson, Arizona – May 8, 2008 - CDEX Inc. (OTCBB: CEXI) announces that it now has seven heparin Signatures in its ValiMed™ Signature Library encompassing a range of concentrations and diluents, including typical neonatal and pediatric doses. (A signature is an electronic fingerprint of a medication at a given concentration in a prescribed diluent.) ValiMed is used both to train compounding pharmtechs/nurses and to validate high-risk medication admixtures, as well as returned narcotics, to provide an increased level of patient safety. ValiMed compares a medication’s spectroscopic signature to the expected signature from the ValiMed database to detect significant medication and concentration errors as well as accidental and deliberate contamination, and provides the results in real time. (For a complete list of the ValiMed Signatures, see www.cdex-inc.com.)
“Based on the recent medication errors and contamination events associated with heparin, our clients requested that we develop an expanded grouping of heparin Signatures for ValiMed,” said Stuart Poteet, Manager of Marketing and Client Support. “The heparin Signatures developed are weighted heavily toward the neonatal and pediatric doses and will provide an increased measure of safety for the patients in hospitals using ValiMed. When the CDEX Team develops a ValiMed signature, we test over 400 separate samples of the medication mixture. Then each potential signature is scrubbed though a number of practical and medical gates and sent through a concentration/dilution study before being placed in the CDEX Library for use by our clients. ValiMed can identify not only significant errors in medication and concentration, but also counterfeit or terrorist contaminated medications before they compromise the pharmaceutical supply chain.”
About CDEX Inc.
CDEX Inc. is a technology development company with a current focus on developing and marketing products using chemical detection and validation technologies. At present, CDEX is applying its resources in two distinct areas: (i) identification of substances of concern (e.g., explosives and illegal drugs for homeland security); and (ii) validation of substances for anti-counterfeiting, brand protection and quality assurance (e.g., validation of prescription medication and detection of counterfeit or sub-par products for brand protection). ValiMed™ is a CDEX solution for the healthcare market. Corporate headquarters and research and development facilities for CDEX are located in Tucson, Arizona. For more information, visit www.cdex-inc.com or contact Malcolm Philips (mphilips@cdex-inc.com) at 520.745.5172 X 210 or 207.
Any statements in this press release which contain information that is not historical are essentially forward-looking, as that term is defined in federal securities laws. Many forward-looking statements can be identified by the use of words such as "expects," "plans," "may," "anticipates," "should," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, THE effectiveness, profitability and marketability of products, the ability to protect proprietary information, AND OTHER risks detailed from time-to-time in filings with the Securities and Exchange Commission. There is no obligation to publicly update any forward-looking statements.